Sensor-Augmented Pump Therapy: description of pediatric patients with Type 1 Diabetes Mellitus (T1D) and initial metabolic outcomes

被引:0
作者
Wong Lam, Carolina [1 ]
Hurtado Navarro, Josefa [2 ]
Fuentes Diaz, Rocio [2 ]
Toro Toro, Elizabeth [1 ]
Reyes Espejo, Barbara [1 ]
机构
[1] Hosp San Juan Dios, Serv Pediat, Unidad Nutr & Diabet Infantil, Santiago, Chile
[2] Univ Chile, Fac Med, Dept Pediat & Cirugia Infantil Occidente, Programa Especialistas Pediat, Santiago, Chile
来源
ANDES PEDIATRICA | 2022年 / 93卷 / 06期
关键词
Type 1 Diabetes Mellitus; Insulin Pump; Sensor Augmented Pump Therapy; Continuous Glucose Monitoring; Time in Range; Time Above Range; Time Below Range; GLYCEMIC VARIABILITY; SATISFACTION; CHILDREN; ADULTS;
D O I
10.32641/andespediatr.v93i6.3923
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The insulin microinfuser with integrated system (SAPT) for patients with type 1 Diabetes Mellitus (T1D) is included in the national financial protection system for high-cost treatments. Objective: To describe the initial and first-year metabolic outcomes and epidemiological and nutritional characte-ristics of T1D pediatric patients treated with SAPT. Patients and Method: Retrospective, descriptive and analytical study of clinical records from 2017 to 2019, of 12 patients with T1D users of SAPT, attended in a referral hospital. Variables: age at program entry, time of evolution of the disease, type of insulin treatment and type of glucose monitoring (capillary: sample or Continuous Glucose Monitoring [CGM]) at program entry, cause of application to the program, nutritional status, rural or urban origin, educational level of the main guardian, HbA1c at application and in the last month of each quarter after SAPT installation, over a 12-month period. HbA1c analysis was venous sample by High-Performance Liquid Chromatography and follow-up was capillary sample by Latex Particle Agglutination Inhibition. Results: The median variables at 12 months of treatment were Total Daily Dose (TDD) 0.74, %Basal (%B) 49%, Time In Range (TIR) 39%, Time Below Range (TBR) 1%, and HbA1c 7.7%. The sensor usage time was met in all cases and only half of them achieved a correct exe-cution of hyperglycemia and hypoglycemia treatment. Inadvertent severe hypoglycemia was the main cause of application to the program. Conclusion: TDD and %B increased, approaching physiological requirement, although without statistical significance, which could be attributed to the administra-tion of adequate insulin with lower risk of hypoglycemia due to predictive suspension and CGM. TIR presented a favorable increase, although not significant, nor reaching the target range, attributable to the short observation time, difficulties in understanding and execution of our patients, and the learning process of the treating clinical team. SAPT was effective in hypoglycemia management and effective in improving HbA1c.
引用
收藏
页码:860 / 867
页数:8
相关论文
共 30 条
  • [1] Apablaza P, 2016, REV MED CLIN CONDES, V27, P213
  • [2] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [3] Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
    Beck, Roy W.
    Bergenstal, Richard M.
    Riddlesworth, Tonya D.
    Kollman, Craig
    Li, Zhaomian
    Brown, Adam S.
    Close, Kelly L.
    [J]. DIABETES CARE, 2019, 42 (03) : 400 - 405
  • [4] Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
    Bergenstal, Richard M.
    Tamborlane, William V.
    Ahmann, Andrew
    Buse, John B.
    Dailey, George
    Davis, Stephen N.
    Joyce, Carol
    Peoples, Tim
    Perkins, Bruce A.
    Welsh, John B.
    Willi, Steven M.
    Wood, Michael A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (04) : 311 - 320
  • [5] Berget Cari, 2019, Diabetes Spectr, V32, P194, DOI 10.2337/ds18-0091
  • [6] Experiences in Sensor-Augmented Pump Therapy in Families with two Children with Type 1 diabetes: A Qualitative Study
    Bomba, Franziska
    Mueller-Godeffroy, Esther
    von Sengbusch, Simone
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2018, 126 (03) : 162 - 167
  • [7] Does Current Diabetes Technology Improve Metabolic Control? A Cross-Sectional Study on the Use of Insulin Pumps and Continuous Glucose Monitoring Devices in a Nationwide Pediatric Population
    Bratke, Heiko
    Margeirsdottir, Hanna D.
    Assmus, Jorg
    Njolstad, Pal R.
    Skrivarhaug, Torild
    [J]. DIABETES THERAPY, 2021, 12 (09) : 2571 - 2583
  • [8] Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study
    Buse, John B.
    Kudva, Yogish C.
    Battelino, Tadej
    Davis, Stephen N.
    Shin, John
    Welsh, John B.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (07) : 644 - 647
  • [9] Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK
    Choudhary, P.
    de Portu, S.
    Arrieta, A.
    Castaneda, J.
    Campbell, F. M.
    [J]. DIABETIC MEDICINE, 2019, 36 (09) : 1100 - 1108
  • [10] International Consensus on Use of Continuous Glucose Monitoring
    Danne, Thomas
    Nimri, Revital
    Battelino, Tadej
    Bergenstal, Richard M.
    Close, Kelly L.
    DeVries, J. Hans
    Garg, Satish
    Heinemann, Lutz
    Hirsch, Irl
    Amiel, Stephanie A.
    Beck, Roy
    Bosi, Emanuele
    Buckingham, Bruce
    Cobelli, Claudio
    Dassau, Eyal
    Doyle, Francis J., III
    Heller, Simon
    Hovorka, Roman
    Jia, Weiping
    Jones, Tim
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Maahs, David
    Murphy, Helen R.
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Saboo, Banshi
    Scharf, Mauro
    Tamborlane, William V.
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2017, 40 (12) : 1631 - 1640